From Name:
From Email:
To Name:
To Email:

Optional Message:


Endpoints for studies of ovarian cancer

from MedPage Today

The time-tested approach of a phase III clinical trial comparing drug A versus drug B has become largely infeasible relative to the myriad of legitimate options based on rapid target discovery, and in the current regulatory environment such investigations are becoming prohibitively costly, time-consuming and are unable to adjust to new discoveries during the course of the trial. This dynamic has placed a premium on reassessing our clinical trials strategy and developing meaningful clinical trial endpoints. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063